Axogenesis factor 1

Drug Profile

Axogenesis factor 1

Alternative Names: AF-1

Latest Information Update: 18 Oct 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Childrens Hospital Boston
  • Developer Alseres Pharmaceuticals
  • Class Nerve growth factors; Neuroprotectants
  • Mechanism of Action Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Spinal cord injuries; Stroke

Most Recent Events

  • 03 Aug 2004 This compound is still in active development
  • 02 Jul 2001 This compound is still in active development
  • 29 Oct 1997 A study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top